Contact
searchSearch
HMP Global
Login

News

News
Pembrolizumab Plus Lenvatinib Shows Promise in Recurrent Gynecologic Clear Cell Carcinomas
02/24/2026
Stephanie Holland
Results from the phase 2 LARA trial demonstrate promising antitumor activity and manageable safety with pembrolizumab plus lenvatinib in patients with recurrent clear cell carcinomas arising from the gynecological tract.
Results from the phase 2 LARA trial demonstrate promising antitumor activity and manageable safety with pembrolizumab plus lenvatinib in patients with recurrent clear cell carcinomas arising from the gynecological tract.
Results from the phase 2 LARA...
02/24/2026
Oncology
Alicia Latham, MD
Conference Coverage
Using Pap-Derived ctDNA for Early Detection of Endometrial Cancer
06/05/2025
Alicia Latham, MD
Alicia Latham, MD, discusses results from a feasibility study which demonstrated the clinical promise of using pap-derived ctDNA to detect endometrial cancer.
Alicia Latham, MD, discusses results from a feasibility study which demonstrated the clinical promise of using pap-derived ctDNA to detect endometrial cancer.
Alicia Latham, MD, discusses...
06/05/2025
Oncology
Conference Coverage
Metformin Added to Letrozole and Abemaciclib Shows Promise in ER-Positive Endometrial Cancer
06/03/2025
Emily Estrada
The addition of metformin to letrozole and abemaciclib induces deeper responses and prolonged PFS vs letrozole and abemaciclib alone in recurrent ER-positive endometrial cancer, according to results from a phase 2 trial.
The addition of metformin to letrozole and abemaciclib induces deeper responses and prolonged PFS vs letrozole and abemaciclib alone in recurrent ER-positive endometrial cancer, according to results from a phase 2 trial.
The addition of metformin to...
06/03/2025
Oncology
Conference Coverage
Metformin Added to Letrozole and Abemaciclib Shows Promise in ER-Positive Endometrial Cancer
06/03/2025
Emily Estrada
The addition of metformin to letrozole and abemaciclib induces deeper responses and prolonged PFS vs letrozole and abemaciclib alone in recurrent ER-positive endometrial cancer, according to results from a phase 2 trial.
The addition of metformin to letrozole and abemaciclib induces deeper responses and prolonged PFS vs letrozole and abemaciclib alone in recurrent ER-positive endometrial cancer, according to results from a phase 2 trial.
The addition of metformin to...
06/03/2025
Oncology
Conference Coverage
Durvalumab With or Without Olaparib Plus Chemotherapy for Patients With Mismatch Repair Proficient Endometrial Cancer
03/19/2025
Allison Casey
Exploratory analyses from the DUO-E trial found chemotherapy plus durvalumab with or without olaparib improved the progression-free survival across multiple subgroups of patients with mismatch proficient advanced or recurrent endometrial...
Exploratory analyses from the DUO-E trial found chemotherapy plus durvalumab with or without olaparib improved the progression-free survival across multiple subgroups of patients with mismatch proficient advanced or recurrent endometrial...
Exploratory analyses from the...
03/19/2025
Oncology
Conference Coverage
Addition of Metformin to Letrozole and Abemaciclib Improves Response, PFS Among Patients With Recurrent Estrogen Receptor-Positive Endometrial Cancer
03/17/2025
Allison Casey
According to results from a phase 2 trial, the addition of metformin to letrozole and abemaciclib improved the response and progression-free survival for estrogen receptor-positive recurrent endometrial cancer.
According to results from a phase 2 trial, the addition of metformin to letrozole and abemaciclib improved the response and progression-free survival for estrogen receptor-positive recurrent endometrial cancer.
According to results from a...
03/17/2025
Oncology
Conference Coverage
Endometrial Sampling Among Patients Who Underwent Transvaginal Ultrasound for Postmenopausal Bleeding
03/17/2025
Allison Casey
A large multicenter study found that two-thirds of patients did not receive a timely endometrial sampling as indicated by a thick endometrium or inadequate viewing upon transvaginal ultrasound for postmenopausal bleeding.
A large multicenter study found that two-thirds of patients did not receive a timely endometrial sampling as indicated by a thick endometrium or inadequate viewing upon transvaginal ultrasound for postmenopausal bleeding.
A large multicenter study found...
03/17/2025
Oncology
News
Pembrolizumab Plus Lenvatinib Did Not Significantly Improve Survival for Patients With Mismatch Repair-Proficient Advanced or Recurrent Endometrial Cancer
12/18/2024
Stephanie Holland
Final results from the phase 3 LEAP-001 study demonstrated that first-line lenvatinib plus pembrolizumab did not significantly improve survival compared to lenvatinib plus chemotherapy among patients with pMMR advanced or recurrent...
Final results from the phase 3 LEAP-001 study demonstrated that first-line lenvatinib plus pembrolizumab did not significantly improve survival compared to lenvatinib plus chemotherapy among patients with pMMR advanced or recurrent...
Final results from the phase 3...
12/18/2024
Oncology
News
Chronic Stress May Contribute to Progression of Metastatic Endometrial Cancer
12/05/2024
Allison Casey
Chronic stress may be associated with progression of metastatic disease, particularly among postmenopausal patients with endometrial cancer and lymph node metastasis.
Chronic stress may be associated with progression of metastatic disease, particularly among postmenopausal patients with endometrial cancer and lymph node metastasis.
Chronic stress may be associated...
12/05/2024
Oncology
News
Dostarlimab Plus Chemotherapy Reduces the Risk of Progression or Death for Patients With dMMR/MSI-H Advanced or Recurrent Endometrial Cancer
11/26/2024
Stephanie Holland
According to additional results from the RUBY trial, dostarlimab plus chemotherapy reduced the risk of progression or death among patients with mismatch repair deficient or microsatellite instability-high advanced or recurrent endometrial...
According to additional results from the RUBY trial, dostarlimab plus chemotherapy reduced the risk of progression or death among patients with mismatch repair deficient or microsatellite instability-high advanced or recurrent endometrial...
According to additional results...
11/26/2024
Oncology

Recent News

News
Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
03/25/2026
Stephanie Holland
Results from arm B of the DREAMM-6 trial demonstrated that belantamab mafodotin plus bortezomib and dexamethasone shows strong clinical promise with manageable safety in relapsed/refractory multiple myeloma.
Results from arm B of the DREAMM-6 trial demonstrated that belantamab mafodotin plus bortezomib and dexamethasone shows strong clinical promise with manageable safety in relapsed/refractory multiple myeloma.
Results from arm B of the...
03/25/2026
Oncology
FDA Approval
FDA Grants Approval to Relacorilant Plus Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer
03/25/2026
Emily Estrada
The FDA approved relacorilant in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic therapies, including bevacizumab.
The FDA approved relacorilant in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic therapies, including bevacizumab.
The FDA approved relacorilant in...
03/25/2026
Oncology
News
Imlunestrant Demonstrates Favorable Safety Alone and With Abemaciclib in Advanced Breast Cancer
03/24/2026
Emily Estrada
Detailed safety findings from the phase 3 EMBER-3 trial further support imlunestrant alone or in combination with abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer.
Detailed safety findings from the phase 3 EMBER-3 trial further support imlunestrant alone or in combination with abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer.
Detailed safety findings from...
03/24/2026
Oncology
News
Early Dose Reductions Improve Persistence With Adjuvant Abemaciclib in High-Risk Early Breast Cancer
03/24/2026
Emily Estrada
Real-world data from the US Flatiron Health Research Database demonstrate that most patients with HR-positive, HER2-negative early breast cancer remain on adjuvant abemaciclib at 6 months, with dosing strategies playing a critical role in...
Real-world data from the US Flatiron Health Research Database demonstrate that most patients with HR-positive, HER2-negative early breast cancer remain on adjuvant abemaciclib at 6 months, with dosing strategies playing a critical role in...
Real-world data from the US...
03/24/2026
Oncology
News
Clinical and Molecular Factors Influence Outcomes of Sevabertinib in HER2-Mutated NSCLC
03/24/2026
Stephanie Holland
Results from an exploratory analysis of the phase 1/2 SOHO-01 study suggest that clinical and molecular characteristics may influence treatment outcomes among patients with HER2-mutated non-small cell lung cancer receiving sevabertinib.
Results from an exploratory analysis of the phase 1/2 SOHO-01 study suggest that clinical and molecular characteristics may influence treatment outcomes among patients with HER2-mutated non-small cell lung cancer receiving sevabertinib.
Results from an exploratory...
03/24/2026
Oncology
News
Pharmacist-Led Interventions Improve Medication Management for Patients Receiving Vorasidenib for Low-Grade Gliomas
03/24/2026
Stephanie Holland
Results from a retrospective, single-center study suggest that pharmacist-led interventions play a critical role in optimizing medication management among patients with low-grade gliomas receiving vorasidenib.
Results from a retrospective, single-center study suggest that pharmacist-led interventions play a critical role in optimizing medication management among patients with low-grade gliomas receiving vorasidenib.
Results from a retrospective,...
03/24/2026
Oncology
FDA Approval
FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Previously Untreated Patients With Advanced Classical Hodgkin Lymphoma
03/20/2026
Emily Estrada
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG...
03/20/2026
Oncology
News
Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative...
03/18/2026
Oncology
News
Belzutifan Plus Lenvatinib Improves PFS in Advanced Clear Cell Renal Cell Carcinoma
03/11/2026
Stephanie Holland
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3...
03/11/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma
03/11/2026
Stephanie Holland
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3...
03/11/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use